-
2024
-
MAY
Out-licensing Agreement with KSBL (SNA-001, Global region)
Fast Track Designation (SNB-101, Small cell lung cancer, FDA)
Orphan Drug Designation (SNB-101, Small cell lung cancer, EMA)
-
FEB
Orphan Drug Designation (SNB-101, Pancreatic cancer, FDA)
-
-
2023
-
SEP
Phase 2 IND approval (SNB-101, Solid tumor, Korea)
-
JUL
Orphan Drug Desingation (SNB-101, Small cell lung cancer, FDA)
-
-
2022
-
DEC
Out-licensing Agreement with Boryung (SNA-001, Korea region)
-
-
2021
-
FEB
Out-licensing Agreement with Boryung (SNB-101, Korea region)
-
-
2020
-
JUN
Phase 1 IND clearance (SNB-101, Solid tumor, FDA)
-
JAN
Granted from NCI (NCL, Nanomedicine Characterization Lab)
-
-
2017
-
MAY
Foundation
-
About us
- About us
- Our History